- New offerings allow PharmaCielo to respond to market demand
with expanded product range
- Extracts derived from proprietary cultivars and produced
internally at 30,000+ sq. ft. processing and extraction
facility
- Independent analytical verification of unique medicinal profile
and high quality
- Current inventories support immediate new product sales
TORONTO and RIONEGRO,
Colombia, Sept. 21, 2020 /CNW/ - PharmaCielo
Ltd. ("PharmaCielo" or the "Company") (TSXV:
PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of
medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings
S.A.S., announced today that it has begun sales and distribution of
an expanded range of medicinal-grade cannabis extracts cultivated
and produced at its Rionegro facilities.
PharmaCielo has been enabled to address customer product
inquiries based on technical experience to date combined with
increased laboratory and processing capabilities and allowing it to
begin commercial production of a significantly expanded range of
extract products that began with CBD Isolate and now
includes Broad Spectrum Oil, CBD Broad Spectrum Distillate,
Water Soluble CBD, CBD Tincture, CBD Distillate Tincture,
Full Spectrum Oil Tincture, THC:CBD Formulations and THC
Distillate.
"The ability to offer a wide range of bulk products which vary
in cannabinoids combination, potency and terpenes content is highly
sought-after in the medicinal and wellness sector, as some specific
products deliver specific benefits, while others can deliver a full
suite of cannabinoid benefits, known as the entourage effect," said
David Attard, CEO of PharmaCielo
Ltd. "With our different formulations we are also able to
provide customers with the flexibility to formulate their final
product according to the individual health and drug delivery
system needs."
Each of PharmaCielo's extracts are derived from unique and
proprietary cultivars developed by the Company's horticultural
research experts, optimized for year-round Colombian open-field
cultivation, with each extract profile reflecting the unique nature
of the cultivar. By example, Broad Spectrum Oil is carefully
purified to yield a beautiful amber coloured cannabinoid-rich
extract that features multiple cannabinoids, including Cannabidiol
(CBD), Cannabidiolic Acid (CBDA), Cannabigerol (CBG),
Cannabichromene (CBC), Cannabidivarin (CBDV) and complemented by a
range of naturally occurring terpenes including Pinene, Limonene,
Linalool, and Myrceneas as part of its attributes.
The expansion of PharmaCielo's product portfolio comes on the
heels of a multi-year investment in its processing and extraction
capabilities. The Company has begun processing part of its
formulations at the expanded facility and is in the position to
meet customer demand for commercial volumes at consistent
high-quality, purity and potency levels required by healthcare
standards.
"As we developed the new product range, based on customer and
prospect demand, our team placed a greater emphasis on ensuring we
added Water Soluble CBD extract to the mix. The development of this
product in particular, will enable PharmaCielo to explore
integration opportunities with major players in the health-oriented
beverage and topical products segments of the market, which have
expressed interest in CBD additives," added Attard.
The Company has begun to accept orders for initial shipments of
the new products in the balance of 2020, with continuing production
capacity and shipments volumes increasing into 2021. The portfolio
of extract products available in commercial volumes appropriate to
the global market is expanding on a continuing basis with future
additional product introductions expected. Individual product
profiles and pricing are available through
sales@pharmacielo.com.
About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO,
OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and
sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered
at its cultivation and processing centre located in Rionegro,
Colombia.
The board of directors and executive team of PharmaCielo are
comprised of a diversely talented group of international business
executives and specialists with relevant and varied expertise.
PharmaCielo recognized the significant role that Colombia's ideal location plays in building a
sustainable business in the medical cannabis industry, and the
Company, together with its directors and executives, is executing
on a business plan focused on supplying the international
marketplace.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of
words such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements include statements with respect to the
Company's delivery of a range of extracts, specific benefits of
products, the expansion of the Company's ability to produce
large volumes of a full product range, the Company's ability to
meet customer commercial demand for volumes, exploration of
integration opportunities with major players in the health-oriented
beverage and topical products segments of the market, the Company
accepting orders for shipments in the remainder of 2020, increasing
production capacity and shipping volumes in 2021 and the Company
expanding its portfolio of extract products available in commercial
volumes. Forward-looking statements are based on
assumptions, including with respect to the Company's ability to
obtain all necessary governmental regulatory approvals to operate
its business, that there are integration opportunities available
with partners in the health-oriented beverage and topical
products segments and that those parties would partner with the
Company, that there will be no unexpected logistical delays
associated with the Company's growth including those related to
COVID 19. Forward-looking statements can be affected by known and
unknown risks, uncertainties and other factors, including, but not
limited to, risk that necessary governmental regulatory approvals
may not be obtained or may not be obtained in time to execute the
Company's business objectives, logistical issues that may prevent
the Company's anticipated growth including those related to COVID
19, the Company's ability to obtain the necessary permits and
licenses it requires in order to export its products from
Colombia and into other countries,
risks associated with the regulation of cannabis and cannabinoid
derivatives, risks associated with operating in Colombia, currency exchange risk, and
additional risks described in the Company's Annual Information Form
for the year ended December 31, 2019
filed with the Canadian securities regulatory authorities under the
Company's SEDAR profile at www.sedar.com. Accordingly, readers
should not place undue reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no obligation
to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE PharmaCielo Ltd.